Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 04:00 ET | Source: Epitopea

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, today announced that...
April 23, 2026 04:00 ET | Source: ENA Respiratory

ENA Respiratory Appoints Melissa Faris to Board

MELBOURNE, Australia, April 23, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic...
April 23, 2026 03:00 ET | Source: PulseSight Therapeutics S.A.S

Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

-Results to be presented at ARVO 2026 Annual Meeting- PARIS, April 23, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive...
April 23, 2026 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
April 23, 2026 01:00 ET | Source: Addex Therapeutics

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
April 23, 2026 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Appoints Orlando Oliveira as Chief Executive Officer

Ad hoc announcement pursuant to Art. 53 LR. Dario Eklund to hand over leadership following planned transition Pratteln, Switzerland, April 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces...
April 22, 2026 19:54 ET | Source: Exicure, Inc.

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.
April 22, 2026 17:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
April 22, 2026 16:05 ET | Source: Abivax

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical...
April 22, 2026 16:05 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 ...